Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.

Nicotinamide phosphoribosyltransferase (Nampt) is a promising anticancer target. Virtual screening identified a thiourea analogue, compound 5, as a novel highly potent Nampt inhibitor. Guided by the cocrystal structure of 5, SAR exploration revealed that the corresponding urea compound 7 exhibited similar potency with an improved solubility profile. These studies also indicated that a 3-pyridyl group was the preferred substituent at one inhibitor terminus and also identified a urea moiety as the optimal linker to the remainder of the inhibitor structure. Further SAR optimization of the other inhibitor terminus ultimately yielded compound 50 as a urea-containing Nampt inhibitor which exhibited excellent biochemical and cellular potency (enzyme IC50 = 0.007 μM; A2780 IC50 = 0.032 μM). Compound 50 also showed excellent in vivo antitumor efficacy when dosed orally in an A2780 ovarian tumor xenograft model (TGI of 97% was observed on day 17).

[1]  N. Curtin,et al.  Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines , 2009, British Journal of Cancer.

[2]  F. Andris,et al.  The Nicotinamide Phosphoribosyltransferase: a Molecular Link between Metabolism, Inflammation, and Cancer the Key Role of Nicotinamide Phosphoribosyl- Transferase in Nicotinamide Adenine Dinucleotide Metabolism , 2022 .

[3]  J. Khan,et al.  Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents , 2006, Nature Structural &Molecular Biology.

[4]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[5]  T. Nakazawa,et al.  Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase. , 2010, Journal of biochemistry.

[6]  P. Canonico,et al.  Synthesis and Biological Evaluation of Isosteric Analogues of FK866, an Inhibitor of NAD Salvage , 2008, ChemMedChem.

[7]  S. Imai,et al.  The NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells* , 2004, Journal of Biological Chemistry.

[8]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[9]  Brett R. Murphy,et al.  Analogues of 4-[(7-Bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methylprop-2-ynylamino]-N-(3-pyridylmethyl)benzamide (CB-30865) as potent inhibitors of nicotinamide phosphoribosyltransferase (Nampt). , 2010, Journal of medicinal chemistry.

[10]  C. N. Coleman,et al.  Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT) Activity by Small Molecule GMX1778 Regulates Reactive Oxygen Species (ROS)-mediated Cytotoxicity in a p53- and Nicotinic Acid Phosphoribosyltransferase1 (NAPRT1)-dependent Manner* , 2012, The Journal of Biological Chemistry.

[11]  Karine Gilbert,et al.  The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors , 2009, Molecular and Cellular Biology.

[12]  Rolf Larsson,et al.  A Phase I study of CHS 828 in patients with solid tumor malignancy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Chi V. Dang,et al.  Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.

[14]  V. Schramm,et al.  A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT , 2009, Proceedings of the National Academy of Sciences.

[15]  C. Brenner,et al.  NAD+ metabolism in health and disease. , 2007, Trends in biochemical sciences.

[16]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[17]  Wieland Kiess,et al.  Nampt: linking NAD biology, metabolism and cancer , 2009, Trends in Endocrinology & Metabolism.

[18]  Chris Twelves,et al.  Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. , 2005, European journal of cancer.

[19]  L. Saltz,et al.  The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor , 2008, Investigational New Drugs.

[20]  L. Binderup,et al.  Novel cyanoguanidines with potent oral antitumour activity , 1997 .

[21]  Sandor Vajda,et al.  Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. , 2007, Journal of medicinal chemistry.

[22]  J. Khan,et al.  Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery , 2007, Expert opinion on therapeutic targets.

[23]  Max Hasmann,et al.  FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. , 2003, Cancer research.

[24]  M. Waring.  Lipophilicity in drug discovery , 2010, Expert Opinion on Drug Discovery.